WAYLIVRAの市場規模、予測、新薬の考察（2032年）

薬剤のサマリー

アポリポタンパクCIII（apoCIII）mRNAのアンチセンスオリゴヌクレオチド阻害薬であるWAYLIVRA（ボラネソーセン）は、家族性部分性脂肪萎縮症（FPL）の治療薬として、Ionis Pharmaceuticalsが子会社のAkcea Therapeuticsを通じて開発中です。家族性部分性脂肪萎縮症（FPL）は、身体のさまざまな部位から選択的かつ進行性に体脂肪（脂肪組織）が減少することを特徴とする稀な遺伝性疾患です。FPL患者は、腕や脚の皮下脂肪が減少していることが多く、頭部や体幹部で脂肪が減少している場合とそうでない場合があります。この薬剤は脂肪萎縮症治療薬としてブラジルでの上市承認を取得しており、米国、欧州、日本で臨床開発中です。

ボラネソーセンはアンチセンスオリゴヌクレオチドで、アポC-III mRNAに結合し、その分解を誘導し、アポC-IIIタンパク質の翻訳を阻害します。通常、アポC-IIIはトリグリセリド代謝とカイロミクロンの肝クリアランスを阻害します。アポC-IIIの翻訳を阻止することにより、これらのトリグリセリドとカイロミクロンの代謝と分解が可能になります。

当レポートでは、主要7市場（米国・ドイツ・フランス・イタリア・スペイン・英国・日本）における脂肪萎縮症向けWAYLIVRAについて調査分析し、作用機序、用法と用量、研究開発活動についての考察、収益の予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 脂肪萎縮症におけるWAYLIVRAの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新治療法）

第5章 WAYLIVRA市場の評価

• 脂肪萎縮症におけるWAYLIVRAの市場見通し
• 主要7市場の分析
  • 主要7市場の脂肪萎縮症向けWAYLIVRAの市場規模
• 市場の分析：国別
  • 米国の脂肪萎縮症向けWAYLIVRAの市場規模
  • ドイツの脂肪萎縮症向けWAYLIVRAの市場規模
  • 英国の脂肪萎縮症向けWAYLIVRAの市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: WAYLIVRA, Clinical Trial Description, 2023
• Table 2: WAYLIVRA, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: WAYLIVRA Market Size in the 7MM, in USD million (2019-2032)
• Table 6: WAYLIVRA Market Size in the US, in USD million (2019-2032)
• Table 7: WAYLIVRA Market Size in Germany, in USD million (2019-2032)
• Table 8: WAYLIVRA Market Size in France, in USD million (2019-2032)
• Table 9: WAYLIVRA Market Size in Italy, in USD million (2019-2032)
• Table 10: WAYLIVRA Market Size in Spain, in USD million (2019-2032)
• Table 11: WAYLIVRA Market Size in the UK, in USD million (2019-2032)
• Table 12: WAYLIVRA Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: WAYLIVRA Market Size in the 7MM, USD million (2019-2032)
• Figure 2: WAYLIVRA Market Size in the United States, USD million (2019-2032)
• Figure 3: WAYLIVRA Market Size in Germany, USD million (2019-2032)
• Figure 4: WAYLIVRA Market Size in France, USD million (2019-2032)
• Figure 5: WAYLIVRA Market Size in Italy, USD million (2019-2032)
• Figure 6: WAYLIVRA Market Size in Spain, USD million (2019-2032)
• Figure 7: WAYLIVRA Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: WAYLIVRA Market Size in Japan, USD million (2019-2032)

"WAYLIVRA Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about WAYLIVRA for lipodystrophy in the seven major markets. A detailed picture of the WAYLIVRA for lipodystrophy in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the WAYLIVRA for lipodystrophy. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the WAYLIVRA market forecast analysis for lipodystrophy in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in lipodystrophy.

Drug Summary:

WAYLIVRA (volanesorsen), an antisense oligonucleotide inhibitor of apolipoprotein CIII (apoCIII) mRNA, is being developed by Ionis Pharmaceuticals through its subsidiary company, Akcea Therapeutics to treat familial partial lipodystrophy (FPL). Familial partial lipodystrophy (FPL) is a rare genetic disorder characterized by selective, progressive body fat loss (adipose tissue) from various body areas. Individuals with FPL often have reduced subcutaneous fat in the arms and legs, and the head and trunk regions may or may not have fat loss. The drug received marketing approval in Brazil for the treatment of lipodystrophy and is investigated under clinical development in the US, Europe and Japan.

Volanesorsen is an antisense oligonucleotide that binds to apoC-III mRNA, leading to its degradation and preventing the translation of apoC-III protein. Normally, apoC-III would inhibit triglyceride metabolism and hepatic clearance of chylomicrons. Preventing translation of apoC-III allows for the metabolism and breakdown of these triglycerides and chylomicrons.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the WAYLIVRA description, mechanism of action, dosage and administration, research and development activities in lipodystrophy.
• Elaborated details on WAYLIVRA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the WAYLIVRA research and development activities in lipodystrophy across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around WAYLIVRA.
• The report contains forecasted sales of WAYLIVRA for lipodystrophy till 2032.
• Comprehensive coverage of the late-stage emerging therapies for lipodystrophy.
• The report also features the SWOT analysis with analyst views for WAYLIVRA in lipodystrophy.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

WAYLIVRA Analytical Perspective by DelveInsight

• In-depth WAYLIVRA Market Assessment

This report provides a detailed market assessment of WAYLIVRA for lipodystrophy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• WAYLIVRA Clinical Assessment

The report provides the clinical trials information of WAYLIVRA for lipodystrophy covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for lipodystrophy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence WAYLIVRA dominance.
• Other emerging products for lipodystrophy are expected to give tough market competition to WAYLIVRA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of WAYLIVRA in lipodystrophy.
• Our in-depth analysis of the forecasted sales data of WAYLIVRA from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the WAYLIVRA in lipodystrophy.

Key Questions:

• What is the product type, route of administration and mechanism of action of WAYLIVRA?
• What is the clinical trial status of the study related to WAYLIVRA in lipodystrophy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the WAYLIVRA development?
• What are the key designations that have been granted to WAYLIVRA for lipodystrophy?
• What is the forecasted market scenario of WAYLIVRA for lipodystrophy?
• What are the forecasted sales of WAYLIVRA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to WAYLIVRA for lipodystrophy?
• Which are the late-stage emerging therapies under development for the treatment of lipodystrophy?

Table of Contents

1. Report Introduction

2. WAYLIVRA Overview in lipodystrophy

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. WAYLIVRA Market Assessment

• 5.1. Market Outlook of WAYLIVRA in lipodystrophy
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of WAYLIVRA in the 7MM for lipodystrophy
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of WAYLIVRA in the United States for lipodystrophy
  • 5.3.2. Market Size of WAYLIVRA in Germany for lipodystrophy
  • 5.3.3. Market Size of WAYLIVRA in France for lipodystrophy
  • 5.3.4. Market Size of WAYLIVRA in Italy for lipodystrophy
  • 5.3.5. Market Size of WAYLIVRA in Spain for lipodystrophy
  • 5.3.6. Market Size of WAYLIVRA in the United Kingdom for lipodystrophy
  • 5.3.7. Market Size of WAYLIVRA in Japan for lipodystrophy

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options